Gabapentin, a prescription drug for shingles nerve pain and added seizure treatment, is now the subject of individual dementia-risk lawsuits. Firms are screening adults with six or more prescriptions for other uses who later received an early-onset dementia or cognitive-impairment diagnosis. There is no nationwide class action. Lawyers file these cases one by one over alleged failure to warn about cognitive risks.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- What research started the claims?
- Why does the reason for use matter?
- Is there a class action to join?
- Who can file under current screening?
What research started the claims?
BMJ Group reported on July 10, 2025 that a study of over 26,000 chronic low-back-pain patients linked six or more gabapentin prescriptions to higher risk within 10 years, with 29% higher dementia and 85% higher mild cognitive impairment risk, as described in BMJ Group's study summary. The same report found adults ages 18-64 with six or more prescriptions were more than twice as likely to develop dementia or cognitive impairment.
The link is an observed association, not proof the drug causes dementia. An MDLinx clinician summary of the work notes prior results were mixed and absolute midlife risk was about one extra case per 100 patients.
Why does the reason for use matter?
The U.S. FDA label for Neurontin lists only management of postherpetic neuralgia in adults and added treatment for partial-onset seizures, as stated in the FDA-approved Neurontin label.
Back pain and many other common uses are therefore off-label. That distinction shapes screening. Firms focus on people prescribed gabapentin for pain or other conditions outside the two approved uses.
Is there a class action to join?
No nationwide gabapentin-dementia class action or federal MDL exists. A 2026 Simmons Hanly Conroy review states suits are filed individually alleging Pfizer failed to warn about cognitive risks, explained in Simmons Hanly Conroy's case review.
Philadelphia created a state-court gabapentinoid mass-tort program on Sept. 8, 2026 for gabapentin and pregabalin cases. The Legal Intelligencer reported 28 cases in the program by mid-October.
Who can file under current screening?
Screening described by Sokolove Law, updated Oct. 13, 2026, generally requires six or more gabapentin uses between 2000-2024, prescription for something other than seizures or shingles nerve pain, plus an early-onset dementia or cognitive-impairment diagnosis, detailed in Sokolove Law's eligibility criteria.
Each firm applies its own review, so meeting the checklist does not guarantee acceptance. Check these points before contacting a firm: Bring the full medication list too, since other conditions and drugs affect memory. A case review moves faster with dates, prescriber names, and diagnosis reports in hand.
- count gabapentin fills from pharmacy records, looking for six or more
- confirm the prescribed reason was not seizures or shingles nerve pain
- confirm the dementia or cognitive-impairment diagnosis, date, and age at onset
- gather prescription bottles, pharmacy printouts, and neurology records